• Products

    A Guide to Hartford Funds

    View Now >

  • Insights

    The Reimagined Human-Centric Investing Podcast

    See What's New >

  • Practice Management

    Applied Insights Team

    Learn More >

  • Resources

    Tax Center

    View Now >

  • About Us

    Be Human-Centric

    Learn More >

Domestic Equity fund

Hartford Healthcare Fund    Share Class - A (HGHAX)


Objective

Seeks long-term capital appreciation.

Overview

A stock fund that invests exclusively in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.


The Health-Care Revolution

The health-care sector is undergoing dramatic changes that will impact everything from the drugs we take to the way patients’ medical records are shared. Aging demographics globally and rising prosperity in emerging-market nations will drive even greater demand for lifesaving drugs, innovative procedures, and disruptive medical technology.

Pipeline to Innovation

With innovation and breakthroughs taking place across the globe, the Fund uses a broadly diversified, global approach that seeks to identify companies with the greatest opportunities in areas including biotechnology, medical technology, health services, and pharmaceuticals.

Backed by Size, Scale, and Experience

Wellington Management, the Fund’s sub-adviser, is one of the largest managers of health care stocks in the world. The portfolio managers on the Fund average 26 years of experience.

Portfolio Management
Senior Managing Director
Global Industry Analyst
22
YRS
MANAGING THIS FUND
24
YRS
AT WELLINGTON MANAGEMENT
35
YRS
EXPERIENCE IN THIS INDUSTRY
Senior Managing Director
Global Industry Analyst
18
YRS
MANAGING THIS FUND
22
YRS
AT WELLINGTON MANAGEMENT
39
YRS
EXPERIENCE IN THIS INDUSTRY
Senior Managing Director
Global Industry Analyst
1
YRS
MANAGING THIS FUND
15
YRS
AT WELLINGTON MANAGEMENT
17
YRS
EXPERIENCE IN THIS INDUSTRY
Managing Director
Global Industry Analyst
0
YRS
MANAGING THIS FUND
7
YRS
AT WELLINGTON MANAGEMENT
15
YRS
EXPERIENCE IN THIS INDUSTRY
Managing Director
Global Industry Analyst
0
YRS
MANAGING THIS FUND
9
YRS
AT WELLINGTON MANAGEMENT
17
YRS
EXPERIENCE IN THIS INDUSTRY
Managing Director
Global Industry Analyst
0
YRS
MANAGING THIS FUND
11
YRS
AT WELLINGTON MANAGEMENT
11
YRS
EXPERIENCE IN THIS INDUSTRY

The portfolio managers are supported by the full resources of Wellington.

Performance

PERFORMANCE %
 
CUMULATIVE %
(as of 4/30/2022)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 4/30/2022)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare A -14.76 -9.88 11.15 9.58 13.93 11.18
With 5.5% Max Sales Charge --- -14.84 9.07 8.34 13.29 10.90
Benchmark -7.87 6.98 15.22 13.55 15.44 ---
Morningstar Health Category -17.60 -13.95 8.83 8.85 13.01 ---
 
CUMULATIVE %
(as of 3/31/2022)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 3/31/2022)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare A -7.61 2.13 13.31 11.69 14.83 11.64
With 5.5% Max Sales Charge --- -3.49 11.20 10.43 14.18 11.35
Benchmark -2.96 17.20 16.21 15.11 16.01 ---
Morningstar Health Category -9.28 -2.53 11.04 11.31 13.94 ---

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

SI = Since Inception. Fund Inception: 05/01/2000

Hartford Healthcare Fund A Share Morningstar Ratings
Morningstar awarded the Fund a
Bronze analyst rating on 10/14/2021
Excludes sales charges. If sales charges and taxes had been included, the value would have been lower.

Characteristics

FUND ESSENTIALS
Inception Date 05/01/2000
Net Assets $1.4 billion
Total Operating Expenses 1.24%
Morningstar Category Health
Lipper Classification Global Health/Biotechnology Funds
CUSIP 416645398
Fund Number 1610
FUND STATS
# of Holdings
101
% in Equities
99
% in Foreign Equities
14
Beta (3 year)
1.04
R Squared (3 year)
0.88
Standard Deviation
17.79%
Turnover- (3/31/2022)
46%
Active Share
57%
Holdings Characteristics
FUND S&P Composite 1500 Health Care Index
Price/Earnings
20.6x 15.4x
Price/Book
4.5x 4.7x
EPS Growth Rate
13.0% 10.1%
Asset Weighted Market Cap (billions)
$132.7 $192.5
Return on Equity
16.7% 24.5%
Median Market Cap (billions)
$7.4 $4.5
Regional Exposure (%)
North America 86
Developed EU & Middle East ex UK 4
Japan 4
United Kingdom 4
Emerging Markets 2
North America 86
Developed EU & Middle East ex UK 4
United Kingdom 4
Japan 4
Emerging Markets 2
Top Ten Holdings (%)
UnitedHealth Group, Inc. 10.33
Eli Lilly & Co. 7.34
Pfizer, Inc. 7.16
Bristol-Myers Squibb Co. 4.81
Danaher Corp. 3.72
Humana, Inc. 3.60
Zoetis, Inc. 3.29
Boston Scientific Corp. 2.96
Edwards Lifesciences Corp. 2.56
Stryker Corp. 2.54
Total Portfolio % 48.31
UnitedHealth Group, Inc. 9.91
Eli Lilly & Co. 7.02
Pfizer, Inc. 6.98
Bristol-Myers Squibb Co. 4.31
Danaher Corp. 4.02
Humana, Inc. 3.26
Boston Scientific Corp. 2.87
Edwards Lifesciences Corp. 2.63
Stryker Corp. 2.60
Becton Dickinson and Co. 2.46
Total Portfolio % 46.06
Market Cap Distribution (%)

Market Cap Header3

Less than $2 billion 4
$2 billion - $5 billion 8
$5 billion - $10 billion 6
Greater than $10 billion 82
Not Classified 0
RETURN CHARACTERISTICS
Alpha (5 Year)
-3.49
Down Capture (5 Year)
112.13
Information Ratio (5 Year)
-0.58
Sharpe Ratio (5 Year)
0.58
Up Capture (5 Year)
95.19
Subsector Exposure
Biopharma Large Cap 32
Medical Technology 31
Health Care Services 26
Biopharma Mid Cap 9
Biopharma Small Cap 2
Medical Technology 33
Biopharma Large Cap 27
Health Care Services 26
Biopharma Mid Cap 10
Biopharma Small Cap 4
Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
distributions and capital gains
Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
12/30/2021 40.42 $0.0000 $0.0000 $0.0000 $0.0000
12/13/2021 38.56 $0.0000 $0.2309 $4.1427 $4.3736
Past distributions are not indicative of future distributions.

Fund Literature


03/31/2022 - PDF (214 KB)
This client flyer summarizes the Fund's investment approach, portfolio statistics, top holdings, and current performance
Morningstar analyst's take on the Hartford Healthcare Fund, which was awarded a Bronze Analyst Rating.
03/31/2022 - PDF (201 KB)
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
03/31/2022 - PDF (537 KB)
Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
PDF (143 KB)
A summary of a fund's full-length prospectus that provides key information potential investors should consider before making an investment decision.
03/31/2022 - PDF (321 KB)
This Pitchbook reviews the Funds' investment approach, investment team, investment process, and general portfolio parameters.
PDF (3 KB)
An unaudited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
PDF (13 KB)
A legal document that discloses essential information about a fund, including investment objectives, risks, fees, expenses, fund manager background and other information.
PDF (3 KB)
An audited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
PDF (13 KB)
A document that supplements the fund's prospectus with additional information about the fund including its operations and risks.
Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and liquidity risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.
227555

The material on this site is for informational and educational purposes only. The material should not be considered tax or legal advice and is not to be relied on as a forecast. The material is also not a recommendation or advice regarding any particular security, strategy or product. Hartford Funds does not represent that any products or strategies discussed are appropriate for any particular investor so investors should seek their own professional advice before investing. Hartford Funds does not serve as a fiduciary. Content is current as of the publication date or date indicated, and may be superseded by subsequent market and economic conditions.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the mutual fund, or ETF summary prospectus and/or prospectus, which can be obtained from a financial professional and should be read carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA|SIPC. ETFs are distributed by ALPS Distributors, Inc. (ALPS). Advisory services may be provided by Hartford Funds Management Company, LLC (HFMC) or its wholly owned subsidiary, Lattice Strategies LLC (Lattice). Certain funds are sub-advised by Wellington Management Company LLP and/or Schroder Investment Management North America Inc (SIMNA). Schroder Investment Management North America Ltd. (SIMNA Ltd) serves as a secondary sub-adviser to certain funds. HFMC, Lattice, Wellington Management, SIMNA, and SIMNA Ltd. are all SEC registered investment advisers. Hartford Funds refers to HFD, Lattice, and HFMC, which are not affiliated with any sub-adviser or ALPS. The funds and other products referred to on this Site may be offered and sold only to persons in the United States and its territories.

© Copyright 2022 Hartford Funds Management Group, Inc. All Rights Reserved. Not FDIC Insured | No Bank Guarantee | May Lose Value